破傷風類毒素疫苗市場規模- 按疫苗類型（破傷風類毒素(TT)、白喉和破傷風(DT)、破傷風和白喉(Td)、五價和白喉、破傷風和百日咳(DTaP)）、年齡層（兒童、成人）），最終用途和預測，2024 - 2032

Tetanus Toxoid Vaccine Market Size - By Vaccine Type (Tetanus Toxoid (TT), Diphtheria and Tetanus (DT), Tetanus and Diphtheria (Td), Pentavalent, & Diphtheria, Tetanus, and Pertussis (DTaP)), Age Group (Pediatric, Adult), End-use & Forecast, 2024 - 2032

出版日期: 2024年02月28日 | 出版商:

Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於人們對疫苗接種重要性的認知不斷提高、免疫計劃的擴大以及疫苗開發和分配基礎設施的進步，破傷風類毒素疫苗市場規模預計在2024 年至2032 年期間將以超過5.8% 的複合年成長率成長。

根據我們的數據世界，破傷風每年奪走全球約 5 萬人的生命，對衛生條件差和疫苗接種覆蓋率不足的地區造成的影響尤為嚴重。與破傷風相關的死亡和殘疾人數不斷增加，凸顯了廣泛免疫工作的迫切需求。隨著人們對破傷風相關風險的認知不斷增強，醫療機構和政府正在加緊努力，擴大疫苗接種計劃並提高疫苗的可及性。對破傷風預防的高度重視正在推動全球對破傷風類毒素疫苗的需求。此外，醫療保健組織和倡導團體正在積極推動疫苗接種運動，以教育社區了解免疫接種在預防破傷風感染和降低死亡率方面的重要性。

破傷風類毒素疫苗市場按疫苗類型、年齡層、最終用途和地區分類。

由於破傷風類毒素 (TT) 疫苗類型在常規免疫計劃和大規模疫苗接種活動中的廣泛使用，預計 2024 年至 2032 年的複合年成長率將達到 5.4%。 TT 疫苗對於預防破傷風非常有效，破傷風是一種由破傷風梭菌引起的潛在致命疾病。這些疫苗也透過刺激人體的免疫反應產生針對破傷風毒素的保護性抗體來誘發免疫力，從而賦予針對疾病的持久免疫力。

預計到2032 年，成人年齡層的破傷風類毒素疫苗市場複合年成長率將達到5.3%。中，例如醫療機構、建築業地點和農田。此外，人口老化和削弱免疫系統的慢性疾病的流行凸顯了成年人接種破傷風疫苗的必要性，以預防與破傷風相關的併發症和死亡。

在人口成長、快速城市化和醫療基礎設施改善的推動下，亞太地區破傷風類毒素疫苗產業預計到 2032 年複合年成長率將達到 6.3%。印度、中國和東南亞國家在醫療保健和免疫計畫方面進行了大量投資，推動了對破傷風類毒素疫苗的需求。此外，擴大免疫計畫（EPI）和在國家免疫計畫中引入含破傷風類毒素的疫苗等措施也有助於區域市場的擴張。

產業生態系統分析
產業影響力
- 成長動力
  - 已開發國家加大疫苗研發力度
  - 一些國家破傷風和白喉病例不斷增加
  - 增加政府疫苗接種計劃計劃
  - 類毒素疫苗研發的技術進展
- 產業陷阱與挑戰
  - 與類毒素疫苗相關的副作用
成長潛力分析
技術景觀
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
競爭定位矩陣
戰略展望矩陣

第 5 章：市場估計與預測：按疫苗類型，2018 年 - 2032 年

主要趨勢
破傷風類毒素 (TT)
白喉和破傷風 (DT)
破傷風和白喉 (Td)
白喉、破傷風和百日咳 (DTaP)
破傷風、白喉和百日咳 (Tdap)
白喉、破傷風、百日咳、Hib 和B型肝炎 (DTP-Hib-HepB)
五價 (DTaP-IPV/Hib)
六價 (DTaP-IPV/Hib-HepB)
其他疫苗類型

第 6 章：市場估計與預測：按年齡分類，2018 - 2032

主要趨勢
兒科
成人

第 7 章：市場估計與預測：按最終用途，2018 - 2032 年

主要趨勢
醫院和診所
政府機構
其他最終用戶

第 8 章：市場估計與預測：按地區分類，2018 年 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Bharat Biotech International Limited
Biological E. Limited
Biological Products Institute (BPI) Argentina
Chengdu Institute of Biological Products Co., Ltd.
GlaxoSmithKline
Johnson & Johnson
Merck & Co., Inc.
Mitsubishi Tanabe Pharma Corporation
Panacea Biotec Limited
Pfizer Inc.
Sanofi
Serum Institute of India
Zydus Group

簡介目錄

Product Code: 8301

Tetanus Toxoid Vaccine Market size is expected to grow at more than 5.8% CAGR during 2024-2032, driven by rising awareness about the importance of vaccination, expanding immunization programs, and advances in vaccine development and distribution infrastructure.

According to Our World in Data, Tetanus claims approximately 50,000 lives globally each year, with a disproportionate impact on regions characterized by poor sanitation and inadequate vaccination coverage. This increasing number of tetanus-related deaths and disabilities is underscoring the urgent need for widespread immunization efforts. As awareness about the risks associated with tetanus grows, healthcare authorities and governments are intensifying their efforts to expand vaccination programs and improve vaccine accessibility. This heightened focus on tetanus prevention is driving the demand for tetanus toxoid vaccines globally. Moreover, healthcare organizations and advocacy groups are actively promoting vaccination campaigns to educate communities about the importance of immunization in preventing tetanus infections and reducing mortality rates.

The tetanus toxoid vaccine market is classified into vaccine type, age group, end-use and region.

The market size from the tetanus toxoid (TT) vaccine type segment is anticipated to record 5.4% CAGR from 2024 to 2032, due to their widespread use in routine immunization programs and mass vaccination campaigns. TT vaccines are highly effective in preventing tetanus, a potentially fatal disease caused by the bacterium Clostridium tetani. These vaccines also induce immunity by stimulating the body's immune response to produce protective antibodies against the tetanus toxin, thereby conferring long-lasting immunity against the disease.

Tetanus toxoid vaccine market from the adult age group segment is expected to witness 5.3% CAGR through 2032. The growth is driven by increasing awareness among adults about the importance of tetanus vaccination, particularly in high-risk occupational settings, such as healthcare facilities, construction sites, and agricultural fields. Additionally, the aging population and the prevalence of chronic medical conditions that weaken the immune system are underscoring the need for tetanus vaccination among adults to prevent tetanus-related complications and fatalities.

Asia Pacific tetanus toxoid vaccines industry is poised to record 6.3% CAGR up to 2032, fueled by population growth, rapid urbanization, and improving healthcare infrastructure. India, China, and Southeast Asian nations are witnessing significant investments in healthcare and immunization programs, driving the demand for tetanus toxoid vaccines. Furthermore, initiatives, such as the Expanded Program on Immunization (EPI) and the introduction of tetanus toxoid-containing vaccines in national immunization schedules are contributing to the regional market expansion.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increase in vaccines research and development in developed nations
  - 3.2.1.2 Growing cases of tetanus and diphtheria in some countries
  - 3.2.1.3 Increasing government initiatives programs for vaccination
  - 3.2.1.4 Technological advancemen in development of toxoid vaccine
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Side-effects associated with toxoid vaccine
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
- 3.6.1 Supplier power
- 3.6.2 Buyer power
- 3.6.3 Threat of new entrants
- 3.6.4 Threat of substitutess
- 3.6.5 Industry rivalry
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategic outlook matrix

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Tetanus toxoid (TT)
5.3 Diphtheria and tetanus (DT)
5.4 Tetanus and diphtheria (Td)
5.5 Diphtheria, tetanus, and pertussis (DTaP)
5.6 Tetanus, diphtheria, and pertussis (Tdap)
5.7 Diphtheria, tetanus, pertussis, Hib and hepatitis B (DTP-Hib-HepB)
5.8 Pentavalent (DTaP-IPV/Hib)
5.9 Hexavalent (DTaP-IPV/Hib-HepB)
5.10 Other vaccine types

Chapter 6 Market Estimates and Forecast, By Age Group, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Pediatric
6.3 Adult

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals and clinics
7.3 Government organizations
7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa